Latest Headlines

Latest Headlines

Baxter, Boston Sci back TVA in $15M round to ease hemodialysis vascular access

The typical approach to achieving consistent and high-quality vascular access for chronic kidney disease patients in need of dialysis is to surgically construct an arteriovenous (AV) fistula, creating a direct connection between an artery and a vein in the arm. Startup TVA Medical has a minimally invasive, catheter-based that can achieve the same goal--only without surgery.

JHL Biotech tests the waters on Taiwan's Emerging Stock Board

Taiwan's JHL Biotech said its listing of an unspecified number of shares on the Taiwan Emerging Stock Board this week has clocked in a value of NTD$1.89 billion ($57.6 million) as it ramps up services in the manufacture and development of biologics in Asia ahead of a potential main board listing.

Precision raises $33.6M for a better prostate biopsy device

Precision Biopsy has raised $33.6 million to develop and commercialize its ClariCore Biopsy System, which is intended to offer a more accurate alternative to ultrasound for guiding prostate biopsies. That's expected to offer improved prostate cancer diagnosis and patient outcomes, as well as reduce the complications associated with biopsy.

NovoCure makes it out with a $165M downsized IPO, trades down 10%

NovoCure has pulled off an enormous $165 million IPO--but the deal wasn't nearly as large as it had hoped for originally. At the last minute, the brain cancer treatment company kicked its existing investors out of selling their 5 million shares in the offering and it also lowered its share price expectations to $22 from an original range of $26 to $29 each.

I-MED Radiology pulls plug on IPO in Australia

Global market volatility claimed another victim as Australia's largest X-ray provider, I-MED Radiology Network, this week pulled its planned $350 million initial public offering, Reuters said.

Australia's Paranta Biosciences raises A$7M for PhI of cystic fibrosis candidate

Australia's Paranta Biosciences has raised A$7 million to fund a Phase I clinical trial of cystic fibrosis treatment candidate PB01, adding to the A$16 million already raised since the company started operations in 2011, as hopes for biotech growth in the country get an official push.

InnFocus raises $33M to back pivotal trial for glaucoma microshunt

InnFocus has nabbed a pair of strategic ophthalmic investors in its Series C financing for $32.8 million. The cash infusion will go to the final phase of clinical testing for the startup's MicroShunt, which is expected to be a minimally invasive alternative to surgery for primary open angle glaucoma.

Sun Pharmaceutical's Shanghvi drops from top spot in Forbes India rich list

Sun Pharmaceutical founder Dilip Shanghvi has dropped from the pinnacle on the  Forbes India  Rich List to the second spot, but plenty of pharmaceutical-related business leaders remain in the top tier.

UPDATED: Allergan's H2 looks lighter without generics, but 10% growth on tap for 2016

What will Allergan look like after it hives off its generics unit to Teva Pharmaceutical Industries? The company unveiled some new numbers on that score Monday. And while the company's status as a potential top 10 pharma company proved short-lived, it's still looking for a growth rate that outpaces its Big Pharma peers.

How much more does the U.S. pay for drugs? Up to 10 times more, report says

The International Federation of Health Plans sifted through insurance data to compare pricing for prescription drugs in countries such as the U.S., Australia, Argentina, Spain and Canada and found enormous differences between the U.S. and other countries.